241 related articles for article (PubMed ID: 12113183)
1. [Therapeutic aspects of HIV/AIDS infected patients and evaluation of therapeutic protocols].
Reszketö Z; Szlávik J; Balogh J; Vincze Z
Acta Pharm Hung; 2001 Dec; 71(4):428-32. PubMed ID: 12113183
[TBL] [Abstract][Full Text] [Related]
2. New antiretrovirals and new combinations.
Havlir DV; Lange JM
AIDS; 1998; 12 Suppl A():S165-74. PubMed ID: 9632999
[TBL] [Abstract][Full Text] [Related]
3. Molecular biological assessment methods and understanding the course of the HIV infection.
Katzenstein TL
APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
[TBL] [Abstract][Full Text] [Related]
4. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
[TBL] [Abstract][Full Text] [Related]
5. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P
HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718
[TBL] [Abstract][Full Text] [Related]
6. Disease progression in HIV-infected patients treated with stavudine vs. zidovudine.
Justice AC; Stein DS; Fusco GP; Sherrill BH; Fusco JS; Danehower SC; Becker SL; Hansen NI; Graham NM;
J Clin Epidemiol; 2004 Jan; 57(1):89-97. PubMed ID: 15019015
[TBL] [Abstract][Full Text] [Related]
7. Tenofovir: new indication. For first-line antiretroviral therapy: wait and see.
Prescrire Int; 2004 Oct; 13(73):180-2. PubMed ID: 15499699
[TBL] [Abstract][Full Text] [Related]
8. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone.
Jones R; Sawleshwarkar S; Michailidis C; Jackson A; Mandalia S; Stebbing J; Bower M; Nelson M; Gazzard BG; Moyle GJ
HIV Med; 2005 Nov; 6(6):396-402. PubMed ID: 16268821
[TBL] [Abstract][Full Text] [Related]
9. Nucleoside analogue-sparing strategy for the treatment of chronic HIV infection: potential interest and clinical experience.
Joly V; Yeni P
Antivir Ther; 2005; 10(1):29-40. PubMed ID: 15751761
[TBL] [Abstract][Full Text] [Related]
10. In vitro analysis of synergism and antagonism of different nucleoside/nucleotide analogue combinations on the inhibition of human immunodeficiency virus type 1 replication.
Perez-Olmeda M; Garcia-Perez J; Mateos E; Spijkers S; Ayerbe MC; Carcas A; Alcami J
J Med Virol; 2009 Feb; 81(2):211-6. PubMed ID: 19107982
[TBL] [Abstract][Full Text] [Related]
11. Anti-HIV drugs.
De Clercq E
Verh K Acad Geneeskd Belg; 2007; 69(2):81-104. PubMed ID: 17550060
[TBL] [Abstract][Full Text] [Related]
12. High prevalence of genotypic resistance to nucleoside reverse transcriptase inhibitors among therapy-naive individuals from the Warsaw cohort.
Horban A; Stanczak JJ; Bakowska E; Tobolewska EJ; Przybylska-Stengiel KJ; Stanczak GP; Burkacka E
Infection; 2002 Dec; 30(6):356-9. PubMed ID: 12478325
[TBL] [Abstract][Full Text] [Related]
13. Indinavir did not further increase mean triglyceride levels in HIV-infected patients treated with nucleoside reverse transcriptase inhibitors: an analysis of three randomized clinical trials.
Rojas C; Coplan PM; Rhodes T; Robertson MN; DiNubile MJ; Guess HA
Pharmacoepidemiol Drug Saf; 2003; 12(5):361-9. PubMed ID: 12899109
[TBL] [Abstract][Full Text] [Related]
14. Impact of PI and NNRTI HAART-based therapy on oral lesions of Brazilian HIV-infected patients.
Ortega KL; Vale DA; Magalhães MH
J Oral Pathol Med; 2009 Jul; 38(6):489-94. PubMed ID: 19453845
[TBL] [Abstract][Full Text] [Related]
15. Diminished selection for thymidine-analog mutations associated with the presence of M184V in Ethiopian children infected with HIV subtype C receiving lamivudine-containing therapy.
Averbuch D; Schapiro JM; Lanier ER; Gradstein S; Gottesman G; Kedem E; Einhorn M; Grisaru-Soen G; Ofir M; Engelhard D; Grossman Z
Pediatr Infect Dis J; 2006 Nov; 25(11):1049-56. PubMed ID: 17072129
[TBL] [Abstract][Full Text] [Related]
16. [Epidemiology of primary drug resistance in chronically HIV-infected patients in Nordrhein-Westfalen, Germany, 2001-2005].
Oette M; Kaiser R; Däumer M; Fätkenheuer G; Rockstroh JK; Knechten H; Mitrenga D; Beerenwinkel N; Sagir A; Pfister H; Häussinger D
Dtsch Med Wochenschr; 2007 May; 132(18):977-82. PubMed ID: 17457780
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy for patients with HIV-1 infection: the use of dual nucleoside analogues with protease inhibitors and other agents.
Gulick R
AIDS; 1998; 12 Suppl 3():S17-22. PubMed ID: 15168719
[TBL] [Abstract][Full Text] [Related]
18. A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.
Pinheiro Edos S; Antunes OA; Fortunak JM
Antiviral Res; 2008 Sep; 79(3):143-65. PubMed ID: 18571246
[TBL] [Abstract][Full Text] [Related]
19. A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients.
Idoko JA; Akinsete L; Abalaka AD; Keshinro LB; Dutse L; Onyenekwe B; Lhekwaba A; Njoku OS; Kehinde MO; Wambebe CO
West Afr J Med; 2002; 21(2):83-6. PubMed ID: 12403023
[TBL] [Abstract][Full Text] [Related]
20. Triple-class antiretroviral drug resistance: risk and predictors among HIV-1-infected patients.
Napravnik S; Keys JR; Quinlivan EB; Wohl DA; Mikeal OV; Eron JJ
AIDS; 2007 Apr; 21(7):825-34. PubMed ID: 17415037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]